Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vivos Therapeutics (VVOS) Cash from Financing Activities (2020 - 2025)

Vivos Therapeutics has reported Cash from Financing Activities over the past 5 years, most recently at $4.3 million for Q4 2025.

  • Quarterly Cash from Financing Activities rose 41.94% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.9 million through Dec 2025, down 22.02% year-over-year, with the annual reading at $18.6 million for FY2025, 3.82% up from the prior year.
  • Cash from Financing Activities was $4.3 million for Q4 2025 at Vivos Therapeutics, up from $2.8 million in the prior quarter.
  • Over five years, Cash from Financing Activities peaked at $25.4 million in Q2 2021 and troughed at -$1.2 million in Q3 2021.
  • The 4-year median for Cash from Financing Activities is $3.6 million (2024), against an average of $5.5 million.
  • The largest YoY upside for Cash from Financing Activities was 1904.8% in 2021 against a maximum downside of 164.4% in 2021.
  • A 4-year view of Cash from Financing Activities shows it stood at -$1.2 million in 2021, then skyrocketed by 403.92% to $3.6 million in 2023, then decreased by 14.41% to $3.1 million in 2024, then soared by 41.94% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Cash from Financing Activities are $4.3 million (Q4 2025), $2.8 million (Q3 2025), and $3.1 million (Q4 2024).